)
)
Vericel Investor Relations Material
Latest events
Q3 2024
Vericel
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Vericel Corporation
Access all reports
Vericel Corporation is a commercial-stage biopharmaceutical company that engages in the research, development, manufacture and distribution of cellular therapies for sports medicine and severe burn care markets. The company has two product candidates: Carticel, its autologous cultured chondrocytes product for the treatment of articular cartilage defects due to degenerative joint diseases; and AlloCello, its ex vivo expanded allogeneic progenitor cells product for the treatment of critical limb ischemia. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Key slides for Vericel Corporation
Q1 2024
Vericel Corporation
Q3 2024
Vericel Corporation
Latest articles
)
What Investors Get Wrong: Chris Mayer on Dividends, Noise, and the Power of Reinvestment
Chris Mayer challenges investor myths on dividends, market noise, and the reinvestment edge. A deep dive into long-term thinking.
29 Nov 2024
)
Evolution: The Live Casino Juggernaut
With ~49% CAGR since its 2015 IPO, 60%+ EBIT margin, and global dominance in live casino, the story of Evolution is truly one for the books.
22 Nov 2024
)
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
Ticker symbol
VCEL
Country
🇺🇸 United States